PTO/SB/08B (01-08)
Approved for use through 04/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				I company to the control of the cont	Complete if Known
Substitu	te 101 101111 1445/F 13	J		Application Number	10/563,189
INF	ORMATIO	N DIS	CLOSURE	Filing Date	December 30, 2005
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Henry Daniell
(Use as many sheets as necessary)				Art Unit	1638
				Examiner Name	Anne R. Kubelik
Sheet	3	of	5	Attorney Docket Number	10669-039

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R21	PETERSON, C. E. et al. " A dynamic model for bilirrubin binding to human serum alburmin", J. Biol. Chem., pp. 20985-20995, Vol. 275.	
- W 2	R22	PETRIDES, D et al. "Computer-aided process analysis and economic evaluation of for biosynthetic human insulin prodution" Biotechnology and Bioengineering, 1995, pp. 529-554, Vol. 48, No. 1. (Abstract)	
	R23	QUIRK, A. V. et al. "Production of recombinant human serum albumin from Saccharomyces cerevisiae", Biotechnol. Appl. Biochem., 1998, pp. 273-287, Vol. 11. (Abstract)	
	R24	ROZKOV, A. et al. "Dynamics of proteolysis and its influence on the accumulation of intracellular recombinant proteins", Enzyme Microbiol. Technol., 2000, pp. 743-748, Vol. 27.	
	R25	RUF, S. et al. "Stable genetic transformation of tomato plastids and expression of a foreign protein in fruit", Nat. Biotechnol., 2001, pp. 870-875, Vol. 19.	
	R26	SAUNDERS, C. W., et al. "Secretion of human serum albumin from Bacillus subtilis", J. Bacteriol., 1987, pp. 2917-2925, Vol. 169.	
	R27	SHIVELY, J. M., et al. "The carboxysome, a prokaryotic organelle" A mini review", Can. J. Bot., 1991, pp. 957-962, Vol. 69.	
	R28	STAUB, J. M. et al. "High-yeild production of a human therapeutic protein in tobacco chloroplasts" Nature Biotechnology, March 2000, pp. 333-338, Vol. 18.	
	R29	STAUB, J. M. et al. "Accumulation of D1 polypeptide in tobacco plastid is regulated via the untranslated region of the psbA mRNA", EMBO J., pp. 601-606, Vol. 12.	
	R30	STAUB, J. M. et al. "Translation of psbA mRNA is regulated by light via the 5'untranslated region in tobacco plastid", Plant, 1994, pp. 547-553, Vol. 6.	

Examiner Date Considered			
	Examiner	Date	
	Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (01-08)
Approved for use through 04/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	Complete if Known		
Substitute for form 1445/1 10	Application Number	10/563,189	
INFORMATION DISCLOSURE	Filing Date	December 30, 2005	
STATEMENT BY APPLICANT	First Named Inventor	Henry Daniell	
(Use as many sheets as necessary)	Art Unit	1638	
(Use as many sneets as necessary)	Examiner Name	Anne R. Kubelik	
Sheet 4 of 5	Attorney Docket Number	10669-039	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R31	TARELLI, E. et al. Recombinant human albumin as a stabilizer for biological materials and for the preparation of international reference reagents", Biologicals, pp. 331-346, Vol. 26.	
	R32	WATANABE, H., et al. "Conformational stability and warfarin-binding properties of hyman serum albumin studied by recombinant mutants", Biochem. J., 2001, pp. 269-274, Vol. 357.	
	R33	WATANABE, H., et al. "In vitro and in vivo properties of recombinant human serum alburmin from Pichia pastoris purified by a method of short processing time", 2001 Pharm. Res., pp. 1775-1781, Vol. 18.	
	R34	ZERGES, W. "Translation in chloroplasts", Biochimie, pp. 583-601, Vol. 82.	
	R35	Daniell, H. "Containment of Herbicide Resistance Through Genetic Engineering of the Chloroplast Genome", Nature Biotech., 1998, pp. 345-348, Vol. 16.	
	R36		
	R37		
	R38		
	R39		
	R40		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 04/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
Substitute for form 1443/1 TO	Application Number	10/563,189	
INFORMATION DISCLOSURE	Filing Date	December 30, 2005	
** ** * * * * * * * * * * * * * * * * *	First Named Inventor	Henry Daniell	
STATEMENT BY APPLICANT	Art Unit	1638	
(Use as many sheets as necessary)	Examiner Name	Anne R. Kubelik	
F	Attorney Docket Number	10660-030	

	U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Number-Kind Code ^{2 (f known)} US-					
		05-					
		US-					
		US-	-				
		US-					
·		US-					
		US-					
	-	US-					
		US-					
		US-					
	-	US-					
		US-					
		US-					
		US-					
		US-					
	-	US-					
		US-					
		US-					
	1	US-					
	 	US-					

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	т6
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	
<u> </u>		WO 01/72959	10-04-2001	Auburn University, et al.	All	
						<u> </u>
						_
				<u> </u>		-
						┡
						<u> </u>

Examiner	Date	
	Considered	
Signature	Considered	
Cignataro		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.